Ayerst's Inderene LA
Executive Summary
Firm submitted ANDA suitability petition for combination of long-acting propranolol plus hydrochlorothiazide with triamterene. Ayerst plans to market capsules in 80/50/75 mg, 120/50/75 mg, and 160/50/75 mg strengths as a "convenient alternative for those patients previously stabilized on a therapeutic regimen of one Inderal LA capsule and one Maxzide tablet daily." The petition cites recent survey data indicating that concomitant use with hydrochlorothiazide/triamterene accounts for 7.7% of total propranolol use.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.